Victory Capital Management Inc Eagle Pharmaceuticals, Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$4.63 - $15.21 $7,741 - $25,431	-1,672 Reduced 5.79%	27,209 $142,000
Q3 2023 Nov 06, 2023	BUY	$15.21 - $22.88 $15 - $22	1 Added 0.0%	28,881 $455,000
Q2 2023 Jul 27, 2023	BUY	$17.74 - $31.87 $182,863 - $328,515	10,308 Added 55.5%	28,880 $561,000
Q1 2023 May 02, 2023	SELL	$25.06 - $34.09 $251,727 - $342,434	-10,045 Reduced 35.1%	18,572 $526,000
Q4 2022 Feb 10, 2023	SELL	$24.98 - $39.77 $67,945 - $108,174	-2,720 Reduced 8.68%	28,617 $836,000
Q4 2022 Feb 09, 2023	BUY	$24.98 - $39.77 $157,174 - $250,232	6,292 Added 25.12%	31,337 $915,000
Q3 2022 Nov 02, 2022	BUY	$26.42 - $47.12 $103,302 - $184,239	3,910 Added 18.5%	25,045 $662,000
Q2 2022 Aug 01, 2022	SELL	$41.26 - $51.35 $20,464 - $25,469	-496 Reduced 2.29%	21,135 $939,000
Q1 2022 May 04, 2022	SELL	$44.58 - $52.6 $137,038 - $161,692	-3,074 Reduced 12.44%	21,631 $955,000
Q4 2021 Feb 07, 2022	BUY	$45.82 - $56.9 $266,764 - $331,271	5,822 Added 30.83%	24,705 $1.26 Million
Q3 2021 Nov 02, 2021	BUY	$43.79 - $55.78 $411,976 - $524,778	9,408 Added 99.29%	18,883 $1.05 Million
Q2 2021 Aug 03, 2021	BUY	$36.86 - $44.5 $120,126 - $145,025	3,259 Added 52.43%	9,475 $406,000
Q1 2021 May 04, 2021	BUY	$40.32 - $50.97 $250,629 - $316,829	6,216 New	6,216 $259,000
Q4 2020 Feb 01, 2021	SELL	$41.72 - $51.34 $260,958 - $321,131	-6,255 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$37.02 - $51.28 $14,808 - $20,512	-400 Reduced 6.01%	6,255 $266,000
Q2 2020 Aug 07, 2020	SELL	$43.24 - $55.02 $46,310 - $58,926	-1,071 Reduced 13.86%	6,655 $319,000
Q1 2020 May 04, 2020	SELL	$34.37 - $60.07 $132,668 - $231,870	-3,860 Reduced 33.32%	7,726 $355,000
Q4 2019 Feb 06, 2020	BUY	$54.32 - $64.31 $200,658 - $237,561	3,694 Added 46.81%	11,586 $696,000
Q4 2019 Feb 04, 2020	BUY	$54.32 - $64.31 $61,598 - $72,927	1,134 Added 16.78%	7,892 $425,000
Q3 2019 Nov 12, 2019	BUY	$53.25 - $59.98 $268,007 - $301,879	5,033 Added 291.77%	6,758 $382,000
Q2 2019 Aug 15, 2019	SELL	$46.61 - $58.45 $139,923 - $175,466	-3,002 Reduced 63.51%	1,725 $96,000
Q1 2019 May 03, 2019	SELL	$38.66 - $51.82 $4,020 - $5,389	-104 Reduced 2.15%	4,727 $239,000
Q4 2018 Feb 05, 2019	SELL	$36.72 - $67.73 $18.6 Million - $34.3 Million	-506,519 Reduced 99.06%	4,831 $195,000
Q3 2018 Nov 01, 2018	SELL	$66.65 - $83.86 $10.3 Million - $13 Million	-155,184 Reduced 23.28%	511,350 $35.5 Million
Q2 2018 Aug 02, 2018	SELL	$51.25 - $76.62 $18 Million - $27 Million	-352,149 Reduced 34.57%	666,534 $50.4 Million
Q1 2018 May 04, 2018	SELL	$52.16 - $66.86 $1.64 Million - $2.11 Million	-31,484 Reduced 3.0%	1,018,683 $53.7 Million
Q4 2017 Feb 01, 2018	BUY	$49.6 - $60.87 $3.58 Million - $4.4 Million	72,217 Added 7.38%	1,050,167 $56.1 Million
Q3 2017 Oct 27, 2017	BUY	$46.62 - $60.36 $446,200 - $577,705	9,571 Added 0.99%	977,950 $58.3 Million
Q2 2017 Aug 07, 2017	BUY	N/A	968,379	968,379 $76.4 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account